Fast Market Research

Small-Cell Lung Cancer - Pipeline Review, H1 2014 - New Market Research Report

New Pharmaceuticals market report from Global Markets Direct: "Small-Cell Lung Cancer - Pipeline Review, H1 2014"

 

Boston, MA -- (ReleaseWire) -- 04/15/2014 -- Global Markets Direct's, 'Small-Cell Lung Cancer - Pipeline Review, H1 2014', provides an overview of the Small-Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned in this Report: Bristol-Myers Squibb Company 28, Boehringer Ingelheim GmbH 29, Amgen Inc. 30, AstraZeneca PLC 31, Eli Lilly and Company 32, GlaxoSmithKline plc 33, Nektar Therapeutics 34, Merck & Co., Inc. 35, Dainippon Sumitomo Pharma Co., Ltd. 36, Aposense Ltd. 37, ZIOPHARM Oncology, Inc. 38, Millennium Pharmaceuticals, Inc. 39, Novartis AG 40, Astellas Pharma Inc. 41, Nippon Kayaku Co., Ltd. 42, Pfizer Inc. 43, A. Menarini Industrie Farmaceutiche Riunite Srl 44, Onyx Pharmaceuticals, Inc. 45, Bayer AG 46, Alchemia Limited 47, ImmunoCellular Therapeutics, Ltd. 48, Immunomedics, Inc. 49, MEI Pharma, Inc. 50, Critical Outcome Technologies Inc. 51, CytRx Corporation 52, Mologen AG 53, Synta Pharmaceuticals Corp. 54, MabVax Therapeutics, Inc. 55, Spectrum Pharmaceuticals, Inc. 56, Supratek Pharma Inc. 57, Oxford BioTherapeutics Ltd 58, TheRyte Ltd. 59, Celator Pharmaceuticals, Inc. 60, Cerulean Pharma, Inc. 61, OncoMed Pharmaceuticals, Inc. 62, Merrimack Pharmaceuticals, Inc. 63, Neotropix, Inc. 64, Mersana Therapeutics, Inc. 65, Cornerstone Pharmaceuticals, Inc. 66, Omnitura Therapeutics Inc. 67, MolMed S.p.A. 68, Laboratorios Farmaceuticos Rovi, S.A. 69, Sunshine Biopharma, Inc. 70, Recombio 71, Mycenax Biotech Inc. 72, Polaris Group 73, CellAct Pharma GmbH 74, centrose llc 75, Zensun (Shanghai) Sci & Tech Co., Ltd. 76, Inbiopro Solutions Pvt. Ltd. 77, AbbVie Inc. 78, Amgen Astellas BioPharma K.K. 79

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Cervical Cancer - Pipeline Review, H1 2014
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Bladder Cancer - Pipeline Review, H1 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014
- Fallopian Tube Cancer - Pipeline Review, H1 2014
- Peritoneal Cancer - Pipeline Review, H1 2014
- Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
- Endometrial Cancer - Pipeline Review, H1 2014